CD8A and neoplasm: Notably, while NHS-IL12 therapy enabled significant increases in the number of CD8+ TILs at the tumor margin, combination therapy facilitated the infiltration of CD8+ TILs in the tumor core, now expressing granzyme B. These observations support increased cytolytic ability by CD8+ lymphocytes in the TME, now able to eliminate tumor cells given their partial recovery of the MHC I allele H-2Kb (Figure 3F).